Caribou Biosciences (CRBU) Receivables - Net (2020 - 2026)
Caribou Biosciences' (CRBU) quarterly Receivables - Net came in at $227000.0 in Q1 2026, up 157.95% year-on-year from $88000.0 in Q1 2025, and up 228.99% on a QoQ basis from $69000.0 in Q4 2025.
Caribou Biosciences (CRBU) Receivables - Net (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of Receivables - Net data on file, last reported at $227000.0 in Q1 2026.
- On a quarterly basis, Receivables - Net rose 157.95% year-over-year to $227000.0 in Q1 2026; TTM through Mar 2026 was $227000.0, a 157.95% increase from a year earlier, with the FY2025 full-year figure at $69000.0, down 73.96% from the prior year.
- Receivables - Net for Q1 2026 stood at $227000.0, up from $69000.0 in the prior quarter.
- Over the last five years, Receivables - Net for CRBU reached as high as $1.5 million in Q1 2023 and fell as low as $69000.0 in Q4 2025.
- Historically, Receivables - Net has averaged $432647.1 across 5 years, with a median of $242000.0 in 2025.
- Across the five-year window, Receivables - Net soared 26100.0% in 2022 and plunged 90.4% in 2025, its largest moves.
- Year by year, Receivables - Net stood at $202000.0 in 2022, then fell by 26.73% to $148000.0 in 2023, then soared by 79.05% to $265000.0 in 2024, then tumbled by 73.96% to $69000.0 in 2025, then surged by 228.99% to $227000.0 in 2026.
- Per Business Quant data, the three most recent Receivables - Net figures were $227000.0 in Q1 2026, $69000.0 in Q4 2025, and $242000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Caribou Biosciences | 156.25 Mn | 38.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Dec 31, 2023 | 148,000.00 |